Skip to main content

Mònica Pons Delgado

Institutions of which they are part

Predoctoral researcher
Liver Diseases
Vall Hebron Institut de Recerca

Mònica Pons Delgado

Institutions of which they are part

Predoctoral researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

De la sencillez en el diagnóstico (no masivo) y seguimiento de la enfermedad hepática crónica avanzada a los complejos mecanismos terapéuticos de las estatinas en modelos animales.

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit, Torrens Buscató, Maria Margarita, Ares Aurora Villagrasa Vilella, Mònica Pons Delgado
Funding agency: Instituto de Salud Carlos III
Funding: 196020
Reference: PI18/00947
Duration: 01/01/2019 - 30/06/2023

Enfermedades hepáticas-Enfermedad crónica hepática avanzada y sus complicaciones.

IP: Joan Genescà Ferrer
Collaborators: Mònica Pons Delgado, Laia Perez Lasarte
Funding agency: Instituto de Salud Carlos III
Funding: 53732
Reference: CM18/00061
Duration: 01/01/2019 - 20/09/2021

Investigación traslacional en complicaciones de la cirrosis: del modelo experimental a la clínica y viceversa

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit, Macarena Simon-Talero Horga, Mònica Pons Delgado
Funding agency: Instituto de Salud Carlos III
Funding: 130075
Reference: PI15/00066
Duration: 01/01/2016 - 31/10/2019

Papel de la elastografía hepática y esplénica en el diagnóstico, seguimiento y tratamiento de la enfermedad crónica hepática avanzada.

IP: Joan Genescà Ferrer
Collaborators: Mònica Pons Delgado
Funding agency: Instituto de Salud Carlos III
Funding: 82400
Reference: FI14/00152
Duration: 01/01/2015 - 31/12/2018

Related news

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

Related professionals

Mireia Andres Villarreal

Mireia Andres Villarreal

Predoctoral researcher
Cardiovascular Diseases
Read more
Xavier Buxo Masip

Xavier Buxo Masip

Predoctoral researcher
Research Group of Physical Medicine and Rehabilitation
Read more
Laura Mónica Perez  Bazan

Laura Mónica Perez Bazan

Main researcher
Research on Aging, Frailty and Transitions in Barcelona
Read more
Estefania De la Torre Villaescusa

Estefania De la Torre Villaescusa

Head of unit
Teaching Promotion
Teaching Area
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.